Guizhi Zhu
Overview
Explore the profile of Guizhi Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
3768
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dain L, Zhu G
Int J Pharm
. 2023 Apr;
638:122924.
PMID: 37037396
Glioblastoma multiforme (GBM) is a deadly and difficult to treat primary brain tumor for which satisfactory therapeutics have yet to be discovered. While cancer immunotherapeutics, such as immune checkpoint inhibitors,...
12.
Su T, Liu X, Lin S, Cheng F, Zhu G
Bioact Mater
. 2023 Mar;
26:169-180.
PMID: 36883121
Ionizable lipid nanocarriers have made historical contribution to COVID-19 mRNA vaccines. Here, we report ionizable polymeric nanoparticles that co-deliver bi-adjuvant and neoantigen peptides for cancer immunotherapy in combination with immune...
13.
Tan X, Zhao Z, Wang R, Zhu G
Front Bioeng Biotechnol
. 2023 Jan;
10:1126876.
PMID: 36686249
No abstract available.
14.
Chen J, Li R, Knapp S, Zhu G, Whitener R, Leiter E, et al.
Front Genet
. 2022 Oct;
13:994501.
PMID: 36276935
Alloxan (AL)-generated Reactive Oxygen Species (ROS) selectively destroy insulin-producing pancreatic β-cells. A previous genome-wide scan (GWS) using a cohort of 296 F2 hybrids between NOD (AL-sensitive) and ALR (AL-resistant) mice...
15.
Su T, Cheng F, Qi J, Zhang Y, Zhou S, Mei L, et al.
Adv Sci (Weinh)
. 2022 Jun;
9(23):e2201895.
PMID: 35712773
Immune checkpoint blockade (ICB) has significantly advanced cancer immunotherapy, yet its patient response rates are generally low. Vaccines, including immunostimulant-adjuvanted peptide antigens, can improve ICB. The emerging neoantigens generated by...
16.
Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G
J Control Release
. 2022 Jun;
348:84-94.
PMID: 35649485
Circular RNAs (circRNA) is a class of natural (biogenic) or synthetic closed RNA without 5' or 3' ends. Meanwhile, their unique covalently-closed structures of circRNA prevent RNA degradation by exonucleases,...
17.
Shen T, Zhang Y, Mei L, Zhang X, Zhu G
Theranostics
. 2022 Jan;
12(1):35-47.
PMID: 34987632
The past decade has witnessed the blossom of nucleic acid therapeutics and diagnostics (theranostics). Unlike conventional small molecule medicines or protein biologics, nucleic acid theranostics have characteristic features such as...
18.
Tang W, Zhang Y, Zhu G
Nanoscale
. 2021 Dec;
14(2):263-276.
PMID: 34918733
Mucosal vaccination can elicit both systemic and mucosal immunity, and therefore has the potential to not only treat mucosal immune diseases, prevent the pathogen infection at the mucosal entry sites,...
19.
Zhou S, Chen W, Cole J, Zhu G
Med Drug Discov
. 2021 Aug;
6.
PMID: 34337382
Cancer immunotherapy has shown great potential as witnessed by an increasing number of immuno-oncology drug approvals in the past few years. Meanwhile, the field of nucleic acid therapeutics has made...
20.
Zhang Y, Shen T, Zhou S, Wang W, Lin S, Zhu G
Adv Ther (Weinh)
. 2021 Aug;
3(9).
PMID: 34337143
Cyclic dinucleotides (CDNs), such as c-di-GMP (CDG), are agonists for stimulator of interferon genes (STING) and are promising for cancer immunotherapy. Yet, the therapeutic efficacy of CDNs has been limited...